Global InformationAmbit Biosciences information
Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases.[1]: 3 [n 1] As of March 2014[update], the company was based in San Diego, California, and consisted of a single facility.[2]: 58 Ambit made an initial public offering in May 2013,[2] and was listed on the NASDAQ exchange under the symbol "AMBI".[3] Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.[4]
- ^ "Form 10-K: Ambit Biosciences Corporation. Commission file number: 001-35919". EDGAR. U.S. Securities and Exchange Commission. March 20, 2014. Retrieved 2017-06-27.
- ^ a b Huggett, Brady (December 2013). "Burning bright". Nature Biotechnology. 31 (12): 1068–1071. doi:10.1038/nbt.2766. PMID 24316634.
- ^ Fidler, Ben (2014-04-01). "Foresite Capital Reloads With New $300M Late-Stage Biotech Fund". Xconomy. Retrieved 2017-06-27.
- ^ "Daiichi Sankyo to Acquire Ambit Biosciences for Up to $410M". GEN - Genetic Engineering and Biotechnology News. 29 September 2014.
Cite error: There are <ref group=n> tags on this page, but the references will not show without a {{reflist|group=n}} template (see the help page).